Polycarbophil is a synthetic, hydrophilic, bulk-forming laxative and antidiarrheal agent. It is a high molecular weight, water-absorbing polymer of acrylic acid cross-linked with divinyl glycol. In the Indian context, it is primarily used for the symptomatic management of constipation and diarrhea associated with conditions like Irritable Bowel Syndrome (IBS), providing a unique dual-action by normalizing stool consistency. It is not systemically absorbed and acts locally within the gastrointestinal lumen.
Adult: 1 to 2 tablets (500mg to 1000mg) orally, 1 to 4 times daily, or as directed. Must be taken with a full glass (240 mL) of water or other fluid.
Note: Tablet must be swallowed whole with at least 240 mL (8 ounces) of water or other clear liquid. Do NOT chew or crush. Taking it without sufficient fluid can cause choking or esophageal obstruction. Dose may be adjusted based on response. Effects may take 12-72 hours.
Polycarbophil is a hydrophilic, water-absorbing polymer. In the intestinal lumen, it absorbs free water, swelling to 60-100 times its original volume. In constipation, it retains water in the stool, increasing bulk, softening the stool, and stimulating peristalsis. In diarrhea, it absorbs excess fecal water, forming a gel and normalizing stool consistency. It does not affect intestinal motility directly.
Pregnancy: Category B (US FDA). No well-controlled studies in pregnant women. Animal studies show no risk. Use only if clearly needed, as systemic absorption is nil. Often considered safe for occasional use.
Driving: No effect. No CNS activity.
| Oral Tetracycline Antibiotics (e.g., Doxycycline) | Polycarbophil may bind to tetracyclines in the GI tract, significantly reducing their absorption and efficacy. | Major |
| Oral Levothyroxine | May impair absorption. Administer levothyroxine at least 4 hours before polycarbophil. | Moderate |
| Digoxin | Theoretical risk of binding; separate administration by at least 2 hours. | Moderate |
| Warfarin and other Oral Anticoagulants | Potential for binding; monitor INR closely if therapy is initiated or discontinued. | Moderate |
| Lithium | May alter lithium levels; monitor serum lithium concentrations. | Moderate |